Back to Clinical Feed
Try:
Front ImmunolInfectious Disease
Targeting VISTA for immunomodulation in sepsis: mechanisms and therapeutic potentials
29 May 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
- Sepsis is a life-threatening clinical syndrome defined as acute organ dysfunction caused by a dysregulated host response to infection. At the core of its pathophysiology lies the aberrant activation and dysregulation of the host immune system.
- The V-domain Ig suppressor of T cell activation (VISTA) is a dual-function immune checkpoint molecule that acts as both a receptor and a ligand, and exerts a pivotal immunoregulatory role in the pathological process of sepsis. Emerging preclinical and clinical evidence indicates that VISTA exerts stage-specific biphasic effects during the progression of sepsis.
- In the early hyperinflammatory phase, VISTA signaling potentially alleviates the cytokine storm and preserves the integrity of organ barriers; in contrast, during the subsequent immunosuppressive (immune paralysis) phase, aberrant VISTA upregulation may drive the sustained hyporesponsiveness of T cells and the tolerogenic reprogramming of myeloid cells. In this review, we systematically summarize and critically appraise the dynamic expression profiles of VISTA across different stages of sepsis, and synthesize current evidence regarding the multifaceted mechanisms by which VISTA modulates both excessive inflammatory responses and immunosuppression.
Clinical Editorial
Summary
Frontiers in Immunology published a clinical update in Infectious Disease on 29 May 2026.
The item focuses on Targeting VISTA for immunomodulation in sepsis: mechanisms and therapeutic potentials.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.
Related by Condition/Drug
Front ImmunolRelated by Conditionsepsis
Immunoglobulin G N-glycosylation predicts outcome in sepsis caused by pathogenic Gram-negative bacteria and Gram-positive bacteria: a nested case-control study
Infectious Disease • 23 Jun 2026
Front ImmunolRelated by Conditionsepsis
HLA DP/DRA molecule regulates systemic inflammation and neuroinflammation, aggravates cognitive impairment and long-term anxiety in murine model of sepsis-associated encephalopathy
Infectious Disease • 16 Jun 2026
ClinicalTrialsRelated by Conditionsepsis
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
Infectious Disease • 22 Apr 2026
ClinicalTrialsRelated by Conditionsepsis
Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU
Infectious Disease • 25 Mar 2026
BMJ OpenRelated by Conditionsepsis
Early versus delayed enteral nutrition in patients with sepsis: a propensity score-matched cohort study at a tertiary hospital in Hebei, China
Research Highlights • 24 Jun 2026
Lan IDRelated by Conditionsepsis
Correction to ATLAS Trial on HIV-Related Sepsis Therapy in Tanzania and Uganda
Infectious Disease • 02 Mar 2026
Feed Metadata
Source
Frontiers in Immunology
Category
Infectious Disease
Published
29 May 2026
Feed Metadata
Source
Frontiers in Immunology
Category
Infectious Disease
Published
29 May 2026